ALL test with LOT rules and updated questions — Desk research brief

Acute Lymphoblastic Leukemia · United States · Build Claims Line of Therapy

Approved · generated 22 Sep 2026, 09:09 UTC · 28 tables, 440 further findings, 27 sources

Verified from a retrieved source Inferred from several sources Original analytical construct Recent update General knowledge Not verified Source = where it came from

Stage 1 — Disease & Diagnostic Foundation

Framework steps: Disease definition and natural history; Epidemiology, incidence, prevalence, mortality; Subtype and molecular/cytogenetic classification; Diagnostic criteria and confirmatory workup; Risk stratification and the patient characteristics that drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)

What happens: This stage establishes the foundational disease understanding for acute lymphoblastic leukemia (ALL) in the United States, including epidemiology, lineage and molecular subtype distinctions, presenting features, diagnostic approaches, and key cohort-defining clinical variables used in pediatric, adolescent/young adult …

Expected output: Epidemiology snapshot table (Metric | Value | Stage or subtype | Source) · Subtype / biology breakdown table (Subtype | Approximate share | Notes) · Diagnostic criteria summary (classification, immunophenotype, cytogenetics, molecular, staging) · Diagnostic workup table · Key clinical variables and cohort-defining forks (age, comorbidity, performance status, organ function) · Key takeaways

Epidemiology snapshot table (Metric | Value | Stage or subtype | Source)

MetricValueStage or subtypeSource
Incidence rate 1.9 per 100,000 men and women per year Acute lymphocytic leukemia overall National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program
Death rate 0.4 per 100,000 men and women per year Acute lymphocytic leukemia overall National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program
Estimated prevalence 126,118 people living with acute lymphocytic leukemia in the United States in 2023 Acute lymphocytic leukemia overall National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program
5-year relative survival 73.2% (2016–2022) Acute lymphocytic leukemia overall National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program
Pediatric incidence 34.0 cases per 1 million persons during 2001–2014 Pediatric ALL CDC / NCHS CDC / NCHS
Peak incidence age Between 2 and 5 years of age Childhood ALL Orphanet Orphanet
Survival after chemotherapy studies Only 49%-69% survived beyond 3 years Adult Philadelphia chromosome-negative B-cell ALL Hematology (Amsterdam, Netherlands) Hematology (Amsterdam, Netherlands)

[VERIFIED] Subtype-specific epidemiology for T-cell ALL and Philadelphia chromosome-positive ALL was not provided in the supplied U.S.-specific evidence.

Subtype / biology breakdown table (Subtype | Approximate share | Notes)

SubtypeApproximate shareNotes
B-cell acute lymphoblastic leukemia (B-ALL) 79.3% Reported as “130 cases (79.3%) were B-cell type”; B-cell markers included CD19, CD22, cytoplasmic CD79a, and frequent CD10 expression. WHO
T-cell acute lymphoblastic leukemia (T-ALL) 20.7% Reported as “34 cases (20.7%) were T-cell type”; cytoplasmic CD3 and CD5 were sensitive diagnostic markers. WHO
Philadelphia chromosome-negative B-cell ALL Not quantified Described as “the most common ALL in adults”; frontline targeted therapy discussion included blinatumomab. Hematology (Amsterdam, Netherlands)
ZNF384-rearranged B-cell ALL Rare subtype Common fusion partners were EP300::ZNF384 (43.3%) and TCF3::ZNF384 (31.7%); kinase/RAS pathway mutations reported in 58.3% of patients. Transplantation and cellular therapy

[VERIFIED] The supplied evidence does not provide a comprehensive WHO/ICC ALL subtype taxonomy or U.S.-specific subtype prevalence estimates.

Diagnostic workup table

Workup componentEvidence from supplied materialsRole in diagnosis
Bone marrow aspiration “Bone marrow aspiration was done at the time of diagnosis.” Used for diagnostic confirmation and morphology assessment. WHO
Morphology and cytochemical analysis Cases “were diagnosed by standard morphology… & cytochemical methods.” Supports acute leukemia classification and blast characterization. WHO
Flow cytometric immunophenotyping “Flow cytometric immunophenotyping provides diagnostic precision.” Supports lineage assignment and subclassification, especially in ambiguous cases. The Libyan journal of medicine
Immunophenotypic lineage markers B-ALL markers included “CD19,CD22 and cytoplasmic CD79a”; T-ALL markers included “Cytoplasmic CD3 and CD5.” Distinguishes B-cell versus T-cell ALL. WHO
Cytogenetics and immunohistochemistry Workup sections included “Immunohistochemistry and Cytogenetics.” Included in diagnostic evaluation framework. Supplied ALL workup excerpts
Lumbar puncture Workup sections included “Lumbar Puncture.” CNS-directed evaluation component referenced in workup structure. Supplied ALL workup excerpts

[VERIFIED] Detailed U.S.-specific molecular testing standards, staging algorithms, and confirmatory diagnostic thresholds were not included in the supplied excerpts.

Further findings

Key takeaways

  1. Claims cohorts should segment pediatric, AYA, and adult ALL because incidence, treatment setting, and survival differ by age.
  2. Lineage assignment requires immunophenotyping-linked cohort logic distinguishing B-ALL versus T-ALL using marrow and flow cytometry evidence.
  3. Molecular subgroup flags should retain Ph-positive, Ph-negative B-ALL, ZNF384 rearrangements, and MRD status because they alter escalation and transplant pathways.
  4. Incident ALL algorithms should combine marrow procedures, morphology, flow cytometry, cytogenetics, and lumbar puncture claims to improve diagnostic specificity.

Stage 2 — Guideline-Based Treatment Landscape & Drug/Biologic Universe

Framework steps: Identify governing guidelines and versions; Treatment settings by stage or phase, and the treatment intent (curative vs. palliative) in each; Map first-line and later-line regimens by treatment setting and guideline preference category; Inventory approved, compendia-supported and off-label agents with label indication, approved line, biomarker restriction and approval date; Capture recent approvals, label expansions, and withdrawn or restricted approvals, with dates; Track how guideline recommendations changed over the study period, with dates; Benchmarks by line and regimen: time on treatment, time to next treatment, PFS, and attrition between lines; Classify therapeutic class and mechanism

What happens: This stage establishes the United States guideline-based treatment landscape and authorized therapy universe for Acute Lymphoblastic Leukemia (ALL) through 2026-09-21 using the supplied evidence. It identifies the major guideline bodies and versions referenced in the evidence, summarizes documented treatment phases and subgroup stratification factors, inventories …

Expected output: Guideline bodies and current versions table (Body | Guideline | Current version) · Treatment settings and intent table (Setting | Intent | Guideline-preferred regimens) · Simplified treatment pathway by setting, risk group / branch point and guideline preference category, with the point at which biomarker testing is expected · Drug and biologic inventory (Agent | Class or MOA | Status: approved / compendia-supported / off-label | Approved line | Biomarker restriction | Approval date | Primary code) · Recent approvals, label expansions, and withdrawn or restricted approvals worth flagging for cohort logic (with dates) · Guideline change log (Date | Body | Change) · Line-of-therapy benchmarks table (Line | Regimen | Time on treatment | Time to next treatment | PFS | Share advancing to the next line | Source) · Key takeaways

Guideline bodies and current versions table (Body | Guideline | Current version)

BodyGuidelineCurrent version
NCCN NCCN Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia (adult ALL) Version 2.2024 Journal of the National Comprehensive Cancer Network : JNCCN
NCCN NCCN Pediatric Acute Lymphoblastic Leukemia guideline Version 2.2025 established_answer synthesis
American Society of Hematology American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults 2026 Blood advances
American Society of Hematology American Society of Hematology 2026 guidelines for relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults 2026 Blood advances

[VERIFIED] The supplied evidence references NCCN adult and pediatric ALL guidelines and 2026 ASH guideline publications but does not provide a comprehensive cross-guideline version inventory.

Treatment settings and intent table (Setting | Intent | Guideline-preferred regimens)

SettingIntentGuideline-preferred regimens
Frontline AYA ALL Initial remission induction/frontline management Pediatric-inspired regimens containing asparaginase compared with traditional adult-inspired protocols Blood advances
Adult ALL induction Remission induction Combination chemotherapy with prednisone, vincristine, and an anthracycline; some regimens add asparaginase or cyclophosphamide National Cancer Institute
Newly diagnosed adult Ph+ ALL Frontline Ph+ disease management Ponatinib with chemotherapy including vincristine/dexamethasone induction, methotrexate/cytarabine consolidation, and vincristine/prednisone maintenance FDA
Relapsed/refractory AYA ALL reinduction Reinduction therapy Blinatumomab and/or inotuzumab over chemotherapy for reinduction Blood advances
First remission higher-risk subsets Consolidation/transplant consideration Allogeneic hematopoietic stem cell transplantation may be indicated for higher-risk subsets or suboptimal responses to initial therapy American Society of Hematology

[VERIFIED] The supplied evidence does not provide NCCN or ASH regimen preference categories beyond the explicitly quoted recommendations.

Drug and biologic inventory (Agent | Class or MOA | Status: approved / compendia-supported / off-label | Approved line | Biomarker restriction | Approval date | Primary code)

AgentClass or MOAStatus: approved / compendia-supported / off-labelApproved lineBiomarker restrictionApproval datePrimary code
Ponatinib (ICLUSIG) Tyrosine kinase inhibitor approved Newly diagnosed adult Ph+ ALL with chemotherapy Philadelphia chromosome-positive ALL 2024-03-19 accelerated approval FDA
Dasatinib (SPRYCEL) Tyrosine kinase inhibitor approved Adults with Ph+ ALL with resistance or intolerance to prior therapy; pediatric patients 1 year and older with newly diagnosed Ph+ ALL in combination with chemotherapy Philadelphia chromosome-positive ALL Initial U.S. Approval: 2006 BRISTOL MYERS SQUIBB
Imatinib mesylate (Gleevec/imatinib) Tyrosine kinase inhibitor approved Adult relapsed/refractory Ph+ ALL; pediatric newly diagnosed Ph+ ALL in combination with chemotherapy Philadelphia chromosome-positive ALL Initial U.S. Approval: 2001 established_answer synthesis NDA021588 established_answer synthesis
Nelarabine (ARRANON) Purine nucleoside analog approved Relapsed/refractory after at least two chemotherapy regimens T-ALL/T-LBL Initial U.S. Approval: 2005 Alembic Pharmaceuticals Limited NDA021877 SANDOZ
Clofarabine injection Purine nucleoside analog approved Pediatric relapsed/refractory ALL after at least two prior regimens Pediatric patients 1 to 21 years old Initial U.S. Approval: 2004 Amneal Pharmaceuticals LLC
Methotrexate Injection Antimetabolite approved Combination chemotherapy regimen or maintenance regimen for adult and pediatric ALL No biomarker restriction stated Initial U.S. Approval: 1953 Hospira, Inc.
TECARTUS (brexucabtagene autoleucel) CAR-T cellular therapy approved Adult relapsed or refractory B-cell precursor ALL B-cell precursor ALL

[VERIFIED] The supplied evidence does not provide HCPCS, CPT, J-codes, NDC mappings, or comprehensive coding identifiers for ALL therapies.

Recent approvals, label expansions, and withdrawn or restricted approvals worth flagging for cohort logic (with dates)

DateRegulatory eventAffected population or scope
2024-03-19 FDA accelerated approval of ponatinib with chemotherapy Adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) FDA
2024-07-31 SPRYCEL SUPPL 28 labeling action Specific ALL population/scope not provided in supplied evidence BRISTOL MYERS SQUIBB
2025-03-11 ARRANON SUPPL 14 labeling action Specific ALL population/scope not provided in supplied evidence SANDOZ
2025-10-10 ICLUSIG SUPPL 38 efficacy supplement Specific ALL population/scope not provided in supplied evidence TAKEDA PHARMS USA
No explicit withdrawn or suspended ALL indication identified Evidence reviewed did not identify explicit ALL approval withdrawal Clofarabine indication described as based upon response rate without verified survival improvement US Food and Drug Administration

[VERIFIED] The supplied evidence contains regulatory supplement histories but often does not specify the indication-level scope of the action.

Guideline change log (Date | Body | Change)

DateBodyChange
2026 American Society of Hematology Pediatric-inspired asparaginase-containing regimens recommended over traditional adult-inspired protocols for frontline AYA ALL American Society of Hematology
2026 American Society of Hematology Blinatumomab and/or inotuzumab recommended over chemotherapy for reinduction in relapsed/refractory AYA ALL American Society of Hematology
2026 American Society of Hematology Allogeneic hematopoietic stem cell transplantation not routinely recommended in first remission but may be indicated for higher-risk subsets or suboptimal responders American Society of Hematology
Contemporary NCCN guidance referenced through 2024 NCCN Risk-stratified treatment approaches based on Philadelphia chromosome status, age, MRD assessment, and cytogenetic/molecular markers Journal of the National Comprehensive Cancer Network : JNCCN

[VERIFIED] The supplied evidence does not provide a complete longitudinal chronology of regimen additions, removals, or preference-category reclassifications.

Line-of-therapy benchmarks table (Line | Regimen | Time on treatment | Time to next treatment | PFS | Share advancing to the next line | Source)

LineRegimenTime on treatmentTime to next treatmentPFSShare advancing to the next lineSource
Newly diagnosed adult ALL induction Multiagent induction regimens Complete response rates range from 60% to 90% National Cancer Institute
Ph+ ALL treated with imatinib-containing therapy Median relapse at 58 days after therapy start Median duration 2.2 months National Cancer Institute
Post-CD19 CAR-T remission context CD19 CAR-T therapy May cure up to 50% of people who receive this therapy National Cancer Institute (NCI)

[VERIFIED] The supplied evidence does not provide comprehensive time-on-treatment, TTNT, or PFS benchmarks by regimen and line of therapy.

Further findings

Key takeaways

  1. Line-of-therapy algorithms should branch by Ph/BCR::ABL1 status, lineage subtype, age group, MRD status, CAR-T exposure, and transplant exposure.
  2. MRD testing appears during treatment transitions and post-CAR-T monitoring; cohort logic should capture repeated MRD assessments.
  3. Claims mapping requires separate handling for frontline Ph+ TKI regimens, relapsed/refractory immunotherapy, CAR-T, and transplant pathways.
  4. Coding enrichment remains incomplete because supplied evidence lacks comprehensive HCPCS, J-code, CPT, and NDC mappings.

Stage 3 — Claims Code Universe: Diagnosis & Procedures

Framework steps: Diagnosis code universe (ICD-10-CM, ICD-9-CM, ICD-11); Procedure, test and encounter codes: diagnostic evidence, non-drug treatment (surgery, radiation, transplant, CAR-T), drug administration, clinical-trial participation; Laboratory and molecular testing codes (LOINC, CPT); Disease-state coding conventions: suspected / rule-out, confirmed, active, remission, relapse, secondary or metastatic, personal history; Observability limitations

What happens: This stage establishes the observable diagnosis, laboratory, and procedure-code universe for Acute Lymphoblastic Leukemia (ALL) in United States claims data through 2026-09-21 using the supplied evidence. The stage identifies ICD-9-CM and ICD-10-CM leukemia diagnosis concepts tied to active disease, remission, and relapse states …

Expected output: Three-system diagnosis code crosswalk (ICD-9-CM legacy | ICD-10-CM current | ICD-11 stem + extension | Description | Effective and retirement dates) · Disease-state code variants (suspected / rule-out, confirmed, active, remission, relapse, secondary or metastatic, personal history Z85) · ICD-11 extension codes for molecular subtypes, layered onto the disease stem · Diagnostic test, procedure and non-drug treatment code universe (Category | Example codes | Purpose) · Drug administration and clinical-trial participation codes (Code | Use | Note) · Monitoring signal table · Observability limitations

Three-system diagnosis code crosswalk (ICD-9-CM legacy | ICD-10-CM current | ICD-11 stem + extension | Description | Effective and retirement dates)

ICD-9-CM legacyICD-10-CM currentICD-11 stem + extensionDescriptionEffective and retirement dates
20400 C91.00 Not provided Acute lymphoid/leukoblastic leukemia not having achieved remission or without mention of remission U.S. National Library of Medicine "The 2026 edition of ICD-10-CM C91.00 became effective on October 1, 2025"; retirement dates not provided Open web
20401 C91.01 Not provided Acute lymphoid/leukoblastic leukemia, in remission U.S. National Library of Medicine Effective and retirement dates not provided U.S. National Library of Medicine
20402 C91.02 Not provided Acute lymphoid/leukoblastic leukemia, in relapse U.S. National Library of Medicine Effective and retirement dates not provided U.S. National Library of Medicine
V1061 Not provided Not provided Personal history of lymphoid leukemia U.S. National Library of Medicine Effective and retirement dates not provided U.S. National Library of Medicine

[VERIFIED] The supplied documents do not provide ICD-11 mappings, ICD-9-to-ICD-10 linkage rules, or retirement-date histories beyond the cited ICD-10-CM effective-date statement.

Disease-state code variants (suspected / rule-out, confirmed, active, remission, relapse, secondary or metastatic, personal history Z85)

Disease-state categoryCode systemCodeDescriptionClaims interpretation
Suspected / rule-out Not provided Not provided Not provided The supplied documents do not provide coding conventions distinguishing suspected versus confirmed ALL diagnoses CMS ICD-10-CM Release Files
Active disease ICD-10-CM C91.00 Acute lymphoblastic leukemia not having achieved remission U.S. National Library of Medicine C91.00 is applicable to "Acute lymphoblastic leukemia with failed remission" and "Acute lymphoblastic leukemia NOS" Open web
Remission ICD-10-CM C91.01 Acute lymphoblastic leukemia, in remission U.S. National Library of Medicine Remission-state ALL diagnosis concept CMS ICD-10-CM Release Files
Relapse ICD-10-CM C91.02 Acute lymphoblastic leukemia, in relapse U.S. National Library of Medicine Relapse-state ALL diagnosis concept CMS ICD-10-CM Release Files
Secondary or metastatic involvement Not provided Not provided Not provided The supplied materials do not provide specific ICD-10-CM secondary malignancy involvement codes CMS ICD-10-CM Release Files
Personal history ICD-9-CM V1061 Personal history of lymphoid leukemia U.S. National Library of Medicine ICD-10-CM personal-history Z85 mappings were not provided U.S. National Library of Medicine

[VERIFIED] The evidence set identifies remission-state coding but does not provide refractory-specific ICD-10-CM codes beyond failed-remission terminology attached to C91.00.

ICD-11 extension codes for molecular subtypes, layered onto the disease stem

ICD-11 stem codeICD-11 extension codeSubtype representedEvidence status
Not provided Not provided Molecular, cytogenetic, immunophenotypic, or lineage-specific ALL subtype The supplied documents do not provide ICD-11 extension codes for ALL subtypes CMS ICD-10-CM Release Files

[VERIFIED] No ICD-11 stem or extension-code mappings were identified in the supplied evidence.

Diagnostic test, procedure and non-drug treatment code universe (Category | Example codes | Purpose)

CategoryExample codesPurpose
Bone marrow aspiration and biopsy HCPCS G0364 "Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service" U.S. National Library of Medicine
Bone marrow biopsy device HCPCS C1830 "Powered bone marrow biopsy needle" U.S. National Library of Medicine
Bone marrow pathology reporting LOINC 33721-2; LOINC 66119-9; LOINC 48807-2 Bone marrow pathology biopsy report and bone marrow aspiration report concepts U.S. National Library of Medicine
Flow cytometry laboratory assessment LOINC 33719-6; 61126-9; 107079-6; 61123-6; 30364-4; 101147-7; 104548-3; 54226-6; 69052-9 Flow cytometry study, blast-cell assessment, lymphocyte/leukocyte quantification, lymphoma panel, and specialist review concepts U.S. National Library of Medicine
FISH cytogenetic testing CPT 88237; 88275; 88271 FISH testing used "for diagnostic and prognostic purposes as well as for follow-up to evaluate patient response to therapy" in pediatric or adult ALL Open web
Radiation therapy and stem cell transplant Specific procedure codes not provided ALL treatment may include "radiation therapy" and "stem cell transplant" Open web

[VERIFIED] The supplied evidence does not provide ICD-10-PCS, leukapheresis, cellular collection, conditioning regimen, CAR-T administration, or comprehensive hematopathology CPT coding.

Drug administration and clinical-trial participation codes (Code | Use | Note)

CodeUseNote
Q0 Investigational clinical service modifier The supplied documents do not provide Q0 modifier definitions or usage Open web
Q1 Routine clinical trial service modifier The supplied documents do not provide Q1 modifier definitions or usage Open web
Drug administration CPT/HCPCS codes Evidence of systemic anti-cancer treatment exposure The supplied documents do not provide CPT and HCPCS drug-administration procedure codes for ALL CMS ICD-10-CM Release Files

[VERIFIED] Evidence was not supplied for chemotherapy administration procedure coding, investigational billing indicators, or routine trial-care markers.

Monitoring signal table

Monitoring conceptPotential signalSupporting code(s)Interpretive note
Active ALL disease Diagnosis claim C91.00 Active disease or failed-remission terminology associated with ALL U.S. National Library of Medicine
Remission monitoring Diagnosis status transition C91.01 Remission-state diagnosis coding identified in ICD-10-CM U.S. National Library of Medicine
Relapse monitoring Diagnosis status transition C91.02 Relapse-state diagnosis coding identified in ICD-10-CM U.S. National Library of Medicine
Bone marrow reassessment Procedure utilization G0364; C1830 Bone marrow aspiration/biopsy and biopsy-device coding may indicate diagnostic or monitoring encounters U.S. National Library of Medicine
Flow cytometry reassessment Laboratory observation LOINC 33719-6; 61126-9; 107079-6 Flow cytometry concepts include blasts/cells and blood assessment U.S. National Library of Medicine
Cytogenetic follow-up FISH testing utilization CPT 88237; 88275; 88271 FISH may be used for follow-up to evaluate patient response to therapy Open web

[INFERENCE] Monitoring interpretations are based on repeated appearance of diagnosis, procedure, and laboratory concepts over time in longitudinal claims or linked laboratory data.

Further findings

Key takeaways

  1. Cohort logic must map legacy ICD-9-CM lymphoid leukemia remission and relapse variants into ICD-10-CM ALL status groupings.
  2. Longitudinal monitoring logic should combine diagnosis transitions with repeated marrow, flow-cytometry, and FISH utilization signals.
  3. Line-of-therapy reconstruction must tolerate absent chemotherapy-administration, CAR-T, transplant, and radiation procedure coding.
  4. Subtype stratification cannot depend on ICD-11 extensions or comprehensive molecular billing coverage in supplied evidence.

Open items

Stage 4 — Treatment Sequencing, Regimen Library & Code Mapping

Framework steps: Define line-of-therapy (LOT) rules; Build the regimen library by line and phase; Map regimen components to HCPCS/J-codes and NDC; Separate pharmacy from medical benefit claims; Define supportive-care exclusions and ambiguity rules

What happens: This stage establishes the evidence-supported building blocks needed for Acute Lymphoblastic Leukemia treatment-sequencing analyses in U.S. claims data, including limited operational cycle logic, identifiable regimen components, HCPCS/J-code mappings, representative NDC examples, administration and dosing references …

Expected output: Line-of-therapy trigger rules (Trigger | Interpretation) · Regimen library (Regimen | Setting | Components) · Component and HCPCS/J-code mapping (Component drug | HCPCS code | Biosimilar / NDC considerations) · NDC universe (Agent | Representative NDCs | Labeler | Coverage note) with a method note for an exhaustive pull · Dosing and administration reference (Agent | Standard adult dosing | Route / schedule | Key administration notes) · Supportive-care and non-therapeutic exclusion list · Ambiguity rules (pharmacy vs medical benefit, same-drug different-intent)

Line-of-therapy trigger rules (Trigger | Interpretation)

TriggerInterpretation
BLINCYTO induction or consolidation cycle consists of 28 days continuous IV infusion followed by 14-day treatment-free interval May support cycle segmentation using 42-day total cycle structure in relapsed/refractory B-cell precursor ALL claims analyses. National Library of Medicine (DailyMed)
BLINCYTO continued therapy consists of 28 days continuous IV infusion followed by 56-day treatment-free interval May support identification of maintenance/continued-treatment intervals with 84-day total cycle structure. National Library of Medicine (DailyMed)
BLINCYTO interruption no longer than 7 days Continue same cycle if interruption after adverse reaction is 7 days or less. National Library of Medicine (DailyMed)
BLINCYTO interruption longer than 7 days Start a new cycle if interruption due to adverse reaction exceeds 7 days. National Library of Medicine (DailyMed)
BESPONSA Cycle 1 duration Cycle 1 is 3 weeks and may be extended to 4 weeks for CR/CRi or toxicity recovery. National Library of Medicine (DailyMed)
BESPONSA subsequent cycles Subsequent cycles are 4 weeks in duration. National Library of Medicine (DailyMed)
BESPONSA interruption greater than 28 days Consider permanent discontinuation after interruption greater than 28 days. National Library of Medicine (DailyMed)
HSCT-directed BESPONSA treatment Recommended duration is 2 cycles for patients proceeding to hematopoietic stem cell transplant (HSCT). National Library of Medicine (DailyMed)
Standard U.S. claims line advancement algorithm No comprehensive claims-based regimen start/stop, relapse episode, maintenance handling, or transplant episode algorithm supplied. National Library of Medicine (DailyMed)

[VERIFIED] Evidence supports therapy-specific cycle and interruption rules only; comprehensive U.S. claims-based line-of-therapy logic was not supplied.

Regimen library (Regimen | Setting | Components)

RegimenSettingComponents
BESPONSA-based therapy Relapsed or refractory CD22-positive B-cell precursor ALL in adult and pediatric patients 1 year and older Inotuzumab ozogamicin. National Library of Medicine (DailyMed)
BLINCYTO-based therapy Relapsed or refractory B-cell precursor ALL Blinatumomab. National Library of Medicine (DailyMed)
FLAG comparator regimen Investigator-choice chemotherapy comparator in relapsed/refractory ALL study Fludarabine + cytarabine + granulocyte colony-stimulating factor. National Library of Medicine (DailyMed)
MXN/Ara-C comparator regimen Investigator-choice chemotherapy comparator in relapsed/refractory ALL study Mitoxantrone + cytarabine. National Library of Medicine (DailyMed)
HIDAC comparator regimen Investigator-choice chemotherapy comparator in relapsed/refractory ALL study High-dose cytarabine. National Library of Medicine (DailyMed)
Methotrexate-containing maintenance regimen Maintenance therapy for ALL Methotrexate as part of combination chemotherapy maintenance regimen. Bryant Ranch Prepack / DailyMed
Mercaptopurine-containing maintenance regimen Maintenance therapy for ALL Mercaptopurine as part of combination chemotherapy maintenance regimen. Hikma Pharmaceuticals USA Inc.
Pediatric-inspired asparaginase-containing regimens Frontline AYA and adult ALL populations Asparaginase-containing pediatric/pediatric-inspired regimens. American journal of hematology
Nelarabine regimen Relapsed/refractory T-ALL/T-LBL after at least two prior chemotherapy regimens Nelarabine. Alembic Pharmaceuticals Limited

[VERIFIED] Sources identify selected therapies and treatment contexts but do not provide a comprehensive ALL regimen library or standardized alias framework.

Component and HCPCS/J-code mapping (Component drug | HCPCS code | Biosimilar / NDC considerations)

Component drugHCPCS codeBiosimilar / NDC considerations
Blinatumomab J9039 HCPCS description states "Injection, blinatumomab, 1 microgram"; alternate HCPCS C9449 also identified. CMS HCPCS Release Files
Inotuzumab ozogamicin J9229 HCPCS description states "Injection, inotuzumab ozogamicin, 0.1 mg"; alternate HCPCS C9028 also identified. CMS HCPCS Release Files
Rituximab J9312 FDA Purple Book identifies biosimilars Truxima (rituximab-abbs), Ruxience (rituximab-pvvr), and Riabni (rituximab-arrx). CMS HCPCS Release Files
Vincristine sulfate J9370 No biosimilar mapping supplied. CMS HCPCS Release Files
Doxorubicin hydrochloride J9000 Injectable doxorubicin formulations identified; no biosimilar mapping supplied. CMS HCPCS Release Files
Cyclophosphamide J9070 No biosimilar mapping supplied. CMS HCPCS Release Files
Methotrexate sodium J9250 and J9260 Multiple formulations and manufacturers identified for methotrexate products. CMS HCPCS Release Files
Cytarabine J9100 No biosimilar mapping supplied. CMS HCPCS Release Files
Daunorubicin hydrochloride J9150 No biosimilar mapping supplied. CMS HCPCS Release Files
Tisagenlecleucel Q2042 HCPCS includes therapeutic-dose CAR-T construct. CMS HCPCS Release Files
Brexucabtagene autoleucel Q2053 HCPCS description includes adult relapsed/refractory B-cell precursor ALL indication language. CMS HCPCS Release Files
Imatinib S0088 HCPCS description states "Imatinib 100 mg." CMS HCPCS Release Files

[VERIFIED] Supplied evidence does not include CPT administration-code linkage or exhaustive multisource generic crosswalks.

NDC universe (Agent | Representative NDCs | Labeler | Coverage note)

AgentRepresentative NDCsLabelerCoverage note
Ponatinib hydrochloride (Iclusig) 63020-533-30; 63020-535-30; 63020-535-60; 63020-536-30 Takeda Pharmaceuticals America, Inc. NDA oral tablet products with multiple strengths and bottle sizes. Takeda Pharmaceuticals America, Inc.
Dasatinib (SPRYCEL) 0003-0528; 0003-0524; 0003-0857 E.R. Squibb & Sons, L.L.C. NDA oral tablet products with multiple strengths including 50 mg, 70 mg, and 140 mg. E.R. Squibb & Sons, L.L.C.
Dasatinib generic 70377-083-11; 70377-085-11; 70377-088-11 Biocon Pharma Inc. ANDA generic oral tablet products. Biocon Pharma Inc.
Clofarabine injection 43598-309-20 Dr. Reddy's Laboratories Inc ANDA intravenous injection product. Dr.Reddy's Laboratories Inc
Nelarabine (Arranon) 0078-0683-61; 66758-165-94 Novartis Pharmaceuticals Corporation; Sandoz Inc Intravenous injection products for T-ALL/T-LBL contexts. Novartis Pharmaceuticals Corporation
Imatinib oral solution (IMKELDI) 81927-201-01 Shorla Oncology Inc. NDA oral solution product. Shorla Oncology Inc.

[ORIGINAL] Exhaustive pull method should combine FDA NDC Directory, DailyMed SPLs, HCPCS release files, and FDA Purple Book product relationships by active ingredient, brand, biosimilar suffix, dosage form, and marketing category.

Dosing and administration reference (Agent | Standard adult dosing | Route / schedule | Key administration notes)

AgentStandard adult dosingRoute / scheduleKey administration notes
Nelarabine 1,500 mg/m² Intravenously over 2 hours on Days 1, 3, and 5 repeated every 21 days Adult relapsed/refractory T-ALL/T-LBL dosing. Alembic Pharmaceuticals Limited
BESPONSA (inotuzumab ozogamicin) Cycle 1 dosing: 0.8 mg/m2 Day 1 and 0.5 mg/m2 Days 8 and 15 Intravenous administration in 21-day cycle extendable to 28 days Cycle extension permitted for CR/CRi or toxicity recovery. National Library of Medicine (DailyMed)
Doxorubicin 60 to 75 mg/m2 every 21 days as single agent; 40 to 75 mg/m2 every 21 to 28 days in combination Intravenous administration Administer over 3 to 10 minutes through central or secure peripheral IV line. US Food and Drug Administration
Mercaptopurine oral suspension 1.5 mg/kg to 2.5 mg/kg (50 mg/m2 to 75 mg/m2) once daily Oral daily administration Used as part of combination chemotherapy maintenance regimen. Hikma Pharmaceuticals USA Inc.
TECARTUS (brexucabtagene autoleucel) 1 × 10^6 CAR-positive viable T cells/kg with maximum 1 × 10^8 cells Intravenous CAR-T administration after lymphodepleting chemotherapy Requires premedication and tocilizumab availability. National Library of Medicine (DailyMed)
Clofarabine 52 mg/m2 daily for 5 consecutive days Intravenous infusion over 2 hours in 28-day cycle Subsequent cycles no sooner than 14 days from prior cycle start; supportive care measures recommended. US Food and Drug Administration
Dasatinib (SPRYCEL) 140 mg once daily for Ph+ ALL context Oral tablet administration Indicated for adults with Ph+ ALL with resistance or intolerance to prior therapy. US Food and Drug Administration

[VERIFIED] Evidence contains selective therapy-specific schedules and does not represent a comprehensive ALL dosing compendium.

Further findings

Key takeaways

  1. The evidence supports therapy-specific cycle and interruption rules for BLINCYTO and BESPONSA but does not provide a complete U.S. claims-based line-of-therapy algorithm.
  2. HCPCS/J-code mappings are directly supported for major infused and cellular ALL therapies including blinatumomab, inotuzumab ozogamicin, rituximab, tisagenlecleucel, and brexucabtagene autoleucel.
  3. Multiple ALL treatment contexts are subpopulation-specific, including relapsed/refractory CD22-positive B-cell precursor ALL, Ph+ ALL, and relapsed/refractory T-ALL/T-LBL after at least two prior regimens.
  4. Representative NDC and package-level evidence exists for oral kinase inhibitors and selected injectables, including ponatinib, dasatinib, clofarabine, nelarabine, and imatinib oral solution products.

Stage 5 — Patient Journey Signals: Discontinuation, Monitoring & Outcomes

Framework steps: Treatment initiation, discontinuation and switching signals; Adverse events and toxicity management; Response, relapse and progression assessment; Monitoring cadence and MRD assessment; End states: transplant, cellular therapy, hospice, death

What happens: This stage establishes how patients with Acute Lymphoblastic Leukemia (ALL) move through treatment monitoring, toxicity management, remission assessment, and downstream outcome states using evidence from chemotherapy, bispecific antibody, antibody-drug conjugate, transplant-related …

Expected output: Discontinuation and adverse-event signals by agent class (Agent class | Signature AE driving discontinuation or switch) · Monitoring and response criteria (Assessment | Tool / criteria) · Patient state model · End-of-journey outcome states · Claims observability table · Key takeaways

Discontinuation and adverse-event signals by agent class (Agent class | Signature AE driving discontinuation or switch)

Agent classSignature AE driving discontinuation or switchClaims-observable or inferable signalEvidence
Bispecific CD19-directed CD3 T-cell engager (BLINCYTO) Cytokine Release Syndrome (CRS); Neurological toxicities including ICANS requiring interruption or discontinuation Hospitalization at cycle start, infusion interruption, therapy restart after gaps, corticosteroid treatment “Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.”; “Interrupt or discontinue BLINCYTO and treat with corticosteroids as recommended.” National Library of Medicine (DailyMed)
CD22-directed antibody-drug conjugate (BESPONSA) Hepatotoxicity including VOD; liver test elevations requiring interruption, dose reduction, or permanent discontinuation Extended treatment cycles, discontinuation before HSCT, liver monitoring encounters “Elevation of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA.”; “Hepatotoxicity, including fatal and life-threatening VOD occurred in patients who received BESPONSA.” National Library of Medicine (DailyMed)
Anthracycline therapy (doxorubicin-containing regimens) Cardiomyopathy; severe myelosuppression; neutropenic fever/infection; extravasation Hospitalization, transfusion claims, delayed cycles, reduced dose intensity, supportive care utilization “Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy”; “Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur.” Pfizer Laboratories Div Pfizer Inc
Vincristine-based therapy Severe toxicities associated with dose reduction Reduced administered dose intensity “Because of severe toxicities, vincristine treatment was significantly reduced (50% of normal dose) in several patients.” Journal of Clinical Oncology
Multiagent chemotherapy regimens Neutropenic fever/infection and unresolved toxicities leading to delayed cycles or dose modification Treatment gaps, supportive care claims, hospitalization “Patients in the NSABP B-15 study could have dose modifications of AC to 75% of the starting doses for neutropenic fever/infection.”; “the next cycle of treatment cycle was delayed until the absolute neutrophil count (ANC) was ≥1000 cells/mm 3 and the platelet count was ≥100,000 cells/mm 3 and nonhematologic toxicities had resolved.” US Food and Drug Administration

[VERIFIED] Supplied documents do not define validated administrative claims algorithms for line-of-therapy construction or switching definitions across all ALL therapies through 2026-09-21.

Monitoring and response criteria (Assessment | Tool / criteria)

AssessmentTool / criteriaClaims observabilityEvidence
Complete remission (CR) “< 5% blasts in the bone marrow,” absence of peripheral blood leukemic blasts, platelet recovery, ANC recovery, and resolution of extramedullary disease Bone marrow biopsy procedures may be observable; remission status itself not directly observable in claims “CR is defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts (platelets ≥ 100 × 10 9 /L and absolute neutrophil counts anc ≥ 1 × 10 9 /L) and resolution of any extramedullary disease.” National Library of Medicine (DailyMed)
Complete remission with incomplete hematologic recovery (CRi) Bone marrow remission with incomplete platelet and/or ANC recovery Laboratory thresholds not directly observable in claims “CRi is defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, incomplete recovery of peripheral blood counts (platelets < 100 × 10 9 /L and/or ANC < 1 × 10 9 /L) and resolution of any extramedullary disease.” National Library of Medicine (DailyMed)
MRD assessment MRD negativity used as treatment milestone; MRD ≥0.1% referenced in indication language MRD laboratory results are not directly observable in administrative claims “A third cycle may be considered for those patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles.”; “CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.” National Library of Medicine (DailyMed)
Bone marrow assessment Bone marrow biopsy reporting and pathology assessment Procedure encounters may be claims-observable “LOINC code 33721-2 is defined as ‘Bone marrow Pathology biopsy report’”; “LOINC code 87014-7 is defined as ‘Guidance for biopsy of Bone marrow’.” U.S. National Library of Medicine
Disease response documentation Disease-specific laboratory results, cytogenetic and molecular markers, staging, and disease status Most response details are registry- or laboratory-based rather than claims-based “Key reporting areas differ depending on the disease reported ... and may include disease type, subtype, transformations, cytogenetic and molecular markers, disease-specific laboratory results, staging, and disease status.” CIBMTR

[VERIFIED] Supplied documents do not provide comprehensive MRD assay workflows, explicit claims observability frameworks, or validated claims-response algorithms through 2026-09-21.

Claims observability table

ConceptClassificationBasisLimitation
Hospitalization during induction or toxicity management DIRECT SIGNAL “You may spend some or much of this time in the hospital, because serious infections or other complications can occur.” American Cancer Society Hospitalization reason and disease severity may not be fully distinguishable in claims
Transfusion requirement DIRECT SIGNAL “requirement for transfusions” associated with severe myelosuppression Pfizer Laboratories Div Pfizer Inc Underlying remission status or toxicity grade is not directly available
Bone marrow biopsy encounter DIRECT SIGNAL “Bone marrow Pathology biopsy report” and “Guidance for biopsy of Bone marrow” LOINC entries U.S. National Library of Medicine Claims do not provide marrow blast percentage or MRD result
Treatment interruption or delayed cycle PROXY SIGNAL Delayed cycles and interruption language described for BLINCYTO and chemotherapy National Library of Medicine (DailyMed); US Food and Drug Administration Gap duration thresholds for discontinuation are not defined
Dose reduction PROXY SIGNAL “50% of normal dose” vincristine reductions and AC dose modifications to “75%” Journal of Clinical Oncology; US Food and Drug Administration Actual administered dose intensity may not be fully measurable across benefit structures
MRD status NOT OBSERVABLE MRD negativity and MRD thresholds are laboratory-defined clinical concepts National Library of Medicine (DailyMed) No supplied claims-based MRD capture methodology
Complete remission status NOT OBSERVABLE CR and CRi definitions rely on marrow blasts and laboratory recovery thresholds National Library of Medicine (DailyMed) Administrative claims lack direct remission result fields
Home infusion and ambulatory monitoring PROXY SIGNAL BLINCYTO may continue as “home infusion therapy” and outpatient monitoring is referenced established answer synthesis Specific coding approaches were not provided in supplied documents

[INFERENCE] Observability classifications reflect whether the supplied evidence describes procedure-, encounter-, or laboratory-based events that could plausibly appear in administrative claims.

Further findings

Key takeaways

  1. Line-of-therapy logic must distinguish planned BLINCYTO 14-day off-treatment intervals from true discontinuation gaps.
  2. Claims algorithms should treat HSCT and CAR-T encounters as major downstream transition states requiring separate pathway flags.
  3. CR, CRi, and MRD outcomes require laboratory or registry linkage because administrative claims lack direct response-result capture.
  4. Dose reductions, infusion interruptions, hospitalization, transfusions, and extended cycles are primary observable toxicity proxies across ALL therapies.

Stage 6 — Unmet Need Synthesis & QA Validation

Framework steps: Compare guidelines vs labels vs literature vs real-world evidence; Identify unmet needs and evidence gaps; Surface contradictions between sources; Document assumptions and limitations; Run QA and SME review readiness assessment

What happens: This stage consolidates unresolved evidence gaps, methodological constraints, observability limitations, and QA considerations affecting construction and validation of claims-derived lines of therapy for Acute Lymphoblastic Leukemia (ALL) in United States administrative data through 2026-09-21. It establishes where published evidence supports only partial inference, where treatment …

Expected output: Unmet-need synthesis (Gap area | Description) · Contradiction table · Assumptions · Limitations · QA checklist · QA / SME sign-off checklist · Readiness assessment

Unmet-need synthesis (Gap area | Description)

Gap areaDescription
Treatment sequencing standardization Adult ALL treatment lacks a single standardized regimen approach because “The standard treatment for adults with ALL consists of many chemotherapy drugs that are given in different combinations and in several steps” and “In adult ALL there is no standard which drugs to give and how to combine them.” Memorial Sloan Kettering Cancer Center
Limited claims-based line definition evidence The supplied evidence provides only isolated examples of claims-oriented sequencing definitions, including “switching from frontline (1 L) pegaspargase (PEG)/calaspargase pegol (CAL-PEG) to second-line (2 L) recombinant Erwinia.” Journal of medical economics
Population heterogeneity Evidence distinguishes molecular and disease subgroups including “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL)” and “Ph+ ALL,” indicating that subgroup classification materially affects treatment interpretation. Hematology (Amsterdam, Netherlands); Memorial Sloan Kettering Cancer Center
Molecular subtype observability Clinically relevant disease characterization includes “EP300::ZNF384,” “TCF3::ZNF384,” and “kinase/RAS pathway mutations,” which depend on specialized molecular testing. Transplantation and cellular therapy
Response and remission ascertainment Key treatment states rely on specialized assessments including “bone marrow morphologic complete remission,” “flow cytometry measurable residual disease (MRD) negative,” and “Pre-transplant MRD was assessed by MFC and RT-qPCR targeting ZNF384 fusion transcripts.” National Cancer Institute (NCI); Transplantation and cellular therapy
Relapse characterization limitations Outcomes literature reports that “nearly half of patients relapsed within 3 years,” but the supplied evidence does not define standardized claims-based relapse algorithms. Hematology (Amsterdam, Netherlands)

All entries summarize limitations or evidence gaps directly supported by supplied quotations. No standardized claims-based ALL line-of-therapy framework was identified in the supplied evidence.

Contradiction table

TopicPotential contradiction or tensionEvidence
Frontline targeted therapy approval scope One source states that “Blinatumomab is currently the only targeted agent approved for frontline treatment,” while the same evidence base also discusses “frontline inotuzumab (±blinatumomab) plus chemotherapy” as showing promise in older populations. This creates potential tension between approved frontline use and investigational or emerging frontline practice patterns. “Blinatumomab is currently the only targeted agent approved for frontline treatment.”; “Frontline inotuzumab (±blinatumomab) plus chemotherapy showed promise in older populations.” Hematology (Amsterdam, Netherlands)
Standardization of adult ALL regimens NCCN-related commentary describes ALL treatment as “one of the most complex and intensive programs in cancer therapy,” while another source states “there is no standard which drugs to give and how to combine them.” Complexity and lack of standardization may complicate claims-derived regimen grouping. “According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL), the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy.”; “In adult ALL there is no standard which drugs to give and how to combine them.” Open web; Memorial Sloan Kettering Cancer Center

Potential contradictions reflect differing descriptions of practice patterns, investigational use, or treatment complexity; no attempt was made to reconcile sources.

QA checklist

QA itemValidation approach
Subpopulation qualification Confirm that analyses preserve subgroup qualifiers such as “Ph- B-ALL” and “Ph+ ALL.” Hematology (Amsterdam, Netherlands); Memorial Sloan Kettering Cancer Center
Molecular testing dependency review Identify concepts dependent on “RT-qPCR,” “flow cytometry,” or molecular fusion testing before assigning claims observability status. Transplantation and cellular therapy; National Cancer Institute (NCI)
Remission and MRD logic review Validate whether remission states such as “MRD-positive CR1” or “MRD negative” are directly available versus inferred. Hematology (Amsterdam, Netherlands); National Cancer Institute (NCI)
Sequencing rule traceability Ensure any frontline-to-second-line sequencing assumptions are explicitly documented when based on examples such as “switching from frontline (1 L) ... to second-line (2 L) recombinant Erwinia.” Journal of medical economics
Longitudinal relapse algorithm validation No supplied evidence defines a validated claims-based relapse detection algorithm. not identified

QA items distinguish directly evidenced concepts from areas lacking validated claims methodology.

QA / SME sign-off checklist

Review areaSME sign-off consideration
Regimen classification Review whether multi-step chemotherapy combinations are grouped consistently given that adult ALL regimens involve “different combinations and ... several steps.” Memorial Sloan Kettering Cancer Center
Molecular subgroup attribution Confirm handling of subgroup-specific terminology including “Ph- B-ALL,” “Ph+ ALL,” and “ZNF384 fusion transcripts.” Hematology (Amsterdam, Netherlands); Memorial Sloan Kettering Cancer Center; Transplantation and cellular therapy
MRD and remission interpretation Review assumptions involving “MRD-positive CR1,” “MRD negative,” and “complete remission (CR).” Hematology (Amsterdam, Netherlands); National Cancer Institute (NCI)
Transplant pathway interpretation Evaluate how analyses handle “allo-HSCT in complete remission (CR)” and “pre-transplant MRD.” Transplantation and cellular therapy

SME review is required for clinically nuanced concepts not directly observable in administrative claims.

Readiness assessment

Assessment areaStatusRationale
Claims-based sequencing readiness Partial Limited evidence exists for explicit line transitions such as “frontline (1 L)” to “second-line (2 L)” switching, but comprehensive sequencing standards were not identified. Journal of medical economics
Molecular stratification readiness Limited Disease characterization depends on molecular findings including “EP300::ZNF384,” “TCF3::ZNF384,” and “kinase/RAS pathway mutations.” Transplantation and cellular therapy
Response outcome readiness Limited Response assessment depends on “flow cytometry measurable residual disease (MRD) negative,” “RT-qPCR,” and bone marrow evaluation. National Cancer Institute (NCI); Transplantation and cellular therapy
Population representativeness readiness Partial Available evidence includes subgroup-specific studies such as “adults with Ph- B-ALL,” limiting applicability to all ALL populations. Hematology (Amsterdam, Netherlands)

Readiness classifications are qualitative syntheses of supplied evidence and do not represent validated scoring systems.

Further findings

Key takeaways

  1. Cohort logic must preserve Ph+ and Ph- subgroup exclusions throughout sequencing and outcome analyses.
  2. Claims-based remission and relapse definitions require proxy assumptions because MRD, NGS, and immunophenotyping results are not directly observable.
  3. Line-of-therapy frameworks must document assumptions for asparaginase switching, discontinuation, and investigational frontline targeted therapy use.
  4. Validation workflows should review transplant eligibility, CNS/EMD classification, and CART persistence concepts separately from claims-derived endpoints.

Open items

Consolidated one-page view

StageCore questionKey deliverableHeadline finding
1. Disease & Diagnostic FoundationWho gets the disease and how is it diagnosed?Disease foundation + diagnostic workup evidence sheetALL cohort construction depends on age setting, lineage immunophenotyping, molecular subgrouping, MRD status, and multimodal marrow-based diagnostic confirmation.
2. Guideline-Based Treatment Landscape & Drug/Biologic UniverseWhat is recommended and what is approved?Guideline-based treatment landscape and approval universeALL treatment guidance and approvals are heavily segmented by biomarker status, lineage, age group, MRD context, and relapsed/refractory setting.
3. Claims Code Universe: Diagnosis & ProceduresHow would the clinical concepts appear in claims?Claims code universe and monitoring-signal mappingALL claims observability is strongest for diagnosis-state transitions and marrow or cytogenetic monitoring, with substantial treatment-coding gaps.
4. Treatment Sequencing, Regimen Library & Code MappingHow does treatment sequence appear in real-world data?Line-of-therapy trigger rules (Trigger | Interpretation); Regimen library (Regimen | SettiThe evidence supports therapy-specific cycle and interruption rules for BLINCYTO and BESPONSA but does not provide a complete U.S. claims-based line-of-therapy algorithm.
5. Patient Journey Signals: Discontinuation, Monitoring & OutcomesHow does a patient move through the clinical journey?Patient-journey signals and monitoring observability briefALL claims journeys are driven by multiphase treatment transitions and toxicity-related utilization patterns, while remission and MRD states remain laboratory-defined.
6. Unmet Need Synthesis & QA ValidationWhere are the gaps, conflicts and limitations?Unmet-need synthesis and QA validation summaryALL claims modelling remains constrained by sparse sequencing standards and dependence on unobservable molecular and MRD assessments.

Sources referenced

Coverage: every number and code in the 39 gathered answers and the finding cards appears in the tables or the findings above. 262 lines were added by the coverage check.